Bio-Techne
Supplies protein reagents, analysis instruments, spatial assays, and diagnostic controls.
Something off on this page? Send us feedback.
Profile
Supplies reagents, assay consumables, and analytical instruments for protein analysis, spatial biology, molecular diagnostics, and clinical quality control to researchers, biopharma companies, and clinical laboratories. Consumables provide most revenue; Protein Sciences is the larger of two segments, and a planned acquisition by Merck KGaA remains pending.
Develops and manufactures life-science reagents, analytical instruments, and diagnostic products for academic researchers, biopharma companies, and clinical laboratories. Protein Sciences, the larger segment, pairs a mostly internally manufactured catalog of proteins, antibodies, small molecules, and immunoassays under R&D Systems, Tocris, and Novus with ProteinSimple platforms for automated western blotting and other protein-analysis workflows.
Diagnostics and Spatial Biology sells RNAscope in-situ hybridization assays, Lunaphore COMET spatial-profiling instruments, Asuragen carrier-screening and oncology kits, and controls and calibrators for clinical diagnostics. Exosome Diagnostics has been divested. Sales span North America, Europe, China, and distributor-served markets, while a broad consumables portfolio supports repeat laboratory workflows. Demand depends on academic and biopharma research, bioprocessing activity, and regulated diagnostic markets. An agreed acquisition by Merck KGaA remains subject to shareholder and regulatory approvals.
Company facts
Categories
Key statistics
Year to date +21.3% · Average volume (30d) 3.1M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 13, 2026 | Wells Fargo | Downgrade | Overweight | Equal Weight | $370 | $73 |
| Jul 9, 2026 | RBC Capital | Downgrade | Outperform | Sector Perform | ||
| Jun 30, 2026 | Benchmark | Downgrade | Buy | Hold | ||
| Jun 30, 2026 | TD Cowen | Downgrade | Buy | Hold | ||
| Jun 29, 2026 | Cowen & Co. | Downgrade | Buy | Hold |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026Q4 FY26 | $0.52 | $0.52 | +0.2% | $314.6M | $321.2M | +2.1% | +0.11% |
| May 6, 2026Q3 FY26 | $0.55 | $0.53 | −3.6% | $316.1M | $311.4M | −1.5% | +7.38% |
| Feb 4, 2026Q2 FY26 | $0.43 | $0.46 | +7.0% | $290.5M | $295.9M | +1.9% | −4.09% |
| Nov 5, 2025Q1 FY26 | $0.42 | $0.42 | −0.3% | $291.3M | $286.6M | −1.6% | −2.94% |
Financial highlights
| 12 quarters | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $316.2M | $317.0M | $286.6M | $295.9M | $311.4M | $321.2M | |
| Gross profit | $214.6M | $198.8M | $188.1M | $191.3M | $208.3M | $211.4M | |
| Operating income | $38.7M | −$23.9M | $47.7M | $54.5M | $75.5M | $74.3M | |
| Net income | $22.6M | −$17.7M | $38.2M | $38.0M | $51.1M | $54.6M | |
| Diluted EPS | $0.14 | −$0.11 | $0.24 | $0.24 | $0.32 | $0.36 | |
| Gross margin | 67.9% | 62.7% | 65.6% | 64.6% | 66.9% | 65.8% | |
| Operating margin | 12.2% | -7.5% | 16.6% | 18.4% | 24.2% | 23.1% |
Fiscal years (4-quarter sums)FY22 $1.11B · FY23 $1.14B · FY24 $1.16B · FY25 $1.22B · FY26 $1.22B
Revenue by product · Q4 FY26
Revenue by geography · Q4 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $264.7M · Total debt $274.2M · Total assets $2.59B · Shareholders' equity $2.11B
Dividends
Raised for 16 straight years. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Aug 24, 2026 | Aug 24 | Sep 4 | $0.08 | |
| Aug 17, 2026 | Aug 17 | Aug 28 | $0.08 | |
| May 18, 2026 | May 18 | May 29 | $0.08 | |
| Feb 13, 2026 | Feb 16 | Feb 27 | $0.08 | |
| Nov 17, 2025 | Nov 17 | Nov 28 | $0.08 | |
| Aug 18, 2025 | Aug 18 | Aug 29 | $0.08 | |
| May 19, 2025 | May 19 | May 30 | $0.08 | |
| Feb 14, 2025 | Feb 17 | Feb 28 | $0.08 |
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 156.57M · Float 155.94M · 99.6% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 14.03M | 8.96% | 13F | Aug 7, 2026 |
| FMR LLC | 12.79M | 8.17% | 13F | Aug 13, 2026 |
| Vanguard Capital Management LLC | 10.22M | 6.53% | 13F | Aug 13, 2026 |
| Goldman Sachs Group Inc | 7.34M | 4.69% | 13F | Aug 14, 2026 |
| HBK Investments L P | 6.83M | 4.36% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 8, 2026 | Amy E. Herr | director | −6,636 | $48.28 |
| Feb 17, 2026 | Amy E. Herr | director | −1,976 | $59.11 |
Peers
- Thermo Fisher Scientific
Reagent-and-instrument giant at $43B revenue contesting every research segment.
- Danaher
Antibody, bioproduction, and protein-analysis platform contesting three pillars.
- 10x Genomics
Spatial biology pure-play — Xenium and Visium HD rival RNAscope and COMET.
- Bio-Rad Laboratories
Western blotting, antibodies, and digital PCR — protein biology research rival.
- Bruker
Spatial biology via CosMx, GeoMx (NanoString), and CellScape spatial proteomics.
- QIAGEN
Molecular diagnostics platform in sample prep, NGS, ctDNA, and oncology assays.
- Repligen
Protein A, chromatography, filtration, and process analytics rival in CGT tools.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Bio-Techne | $72.36 | +0.01% | $11.33B | 62.4 | 34.9 | 9.3 | +1.3% |
| Thermo Fisher Scientific | $620.01 | −0.32% | $231.22B | 33.5 | 23.7 | 5.0 | +10.5% |
| Danaher | $215.50 | −0.25% | $151.89B | 38.4 | 24.3 | 6.0 | +5.5% |
| 10x Genomics | $61.54 | −0.01% | $7.81B | — | — | 12.7 | −12.7% |
| Bio-Rad Laboratories | $387.70 | +0.02% | $10.44B | 47.0 | 37.6 | 4.0 | −0.1% |
| Bruker | $57.08 | +0.04% | $8.69B | — | 25.2 | 2.5 | +5.2% |
| QIAGEN | $43.00 | −0.28% | $8.89B | 22.1 | 17.3 | 4.2 | +0.3% |
| Repligen | $181.00 | +2.72% | $9.95B | 241.5 | 78.1 | 12.7 | +11.9% |
| Median | 38.4 | 24.8 | 5.0 | +5.2% |